MorphoSys And The University Of Melbourne File New Patent Applications In MOR103 Program
MorphoSys AG (FSE MOR; Prime Standard Segment, TecDAX) and the University of Melbourne announced today an agreement to cooperate on investigating new therapeutic applications for MorphoSyss MOR103 program. MOR103, a HuCAL antibody against human GMCSF (Granulocyte macrophagecolony stimulating factor), is currently in development for the treatment of rheumatoid arthritis (RA). The collaboration announced today [...]